Research Articles
 Activity of sorafenib against desmoid tumor/deep fibromatoses
Sorafenib is active against desmoid tumors. A prospective, randomized clinical trial of sorafenib against other active agents is warranted. Loss of MRI T2 signal may be a useful surrogate for defining responses, but requires validation by examination of tumor pathology.
Clin Cancer Res June 15, 2011 17:4082-4090; Published OnlineFirst March 29, 2011;
- Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF).
A response of a patient to sorafenib on an expanded access program led us to review our experience with sorafenib for pts with DT/DF.
Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 28, No 15_suppl (May 20 Supplement), 2010: 10013
© 2010 American Society of Clinical Oncology
- Physician’s gift establishes center to help others with colorectal disease
Sanford R. Weiss, MD, of San Francisco has left a legacy: His $7.2 million transformational gift establishes the Sanford R. Weiss, MD, Center for Hereditary Colorectal Neoplasia and provides an unprecedented opportunity to investigate the disease and to treat and educate patients.
- Multidisciplinary treatment for an enigmatic disease
Physicians face challenges in both the diagnosis and treatment of Desmoid tumors. At The University of Texas MD Anderson Cancer Center, a multidisciplinary team is working to address these challenges.
- Sumer's Radiology blog, CT v MRI on desmoid tumors,
Desmoid tumors have a similar attenuation to muscle on contrast-enhanced CT images. However, CT cannot distinguish a desmoid tumor from similar soft tissue tumors, making histological diagnosis necessary. MRI enables better tissue characterization of desmoid tumors by demonstrating intratumoral areas of low signal intensity on all pulse sequences...
- COX-2 Inhibitor Potential Treatment for Extraabdominal Desmoid Tumors
Meloxicam (Mobic), a cyclooxygenase (COX)-2 inhibitor drug used for arthritis, has shown promise as a treatment for extraabdominal desmoid tumors, according to the results of a small pilot study.
Requires Medscape account (free)
- MGH to use genetics to personalize cancer care
Cancer doctors at Massachusetts General Hospital plan within a year to read the genetic fingerprints of nearly all new patients' tumors, a novel strategy designed to customize treatment
- NIH Launches Drug-Development Program for Rare Diseases
The National Institutes of Health is wading into the drug development process by launching a program aimed at finding and getting new drugs ready for testing in humans with rare diseases... from the Wall Street Journal
- Hereditary desmoid disease (HDD)
Hereditary desmoid disease Health Article from Healthline.com
- Sarcomas and Cancer Predisposition Syndromes
An ESUN Article by Abha Gupta, MD and David Malkin, MD to review common genetic or heritable conditions associated with sarcomas.
- 2008 CTOS Presentations (excerpts)
The Connective Tissue Oncology Society was formed in 1995 and incorporated in 1997. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues. The goal of the society is to advance the care of patients with connective tissue tumors and to increase knowledge of all aspects of the biology of these tumors, including basic and clinical research.
- Article from the University of Illinois Medical Center references DTRF. SURGEONS REMOVE LARGE TUMOR, TRANSPLANT BOWEL BACK INTO PATIENT
Surgeons at the University of Illinois Medical Center at Chicago removed an 11-pound desmoid tumor from the abdominal cavity of an Arkansas man and performed a transplant using a segment of his own small intestine rescued during surgery, preserving his ability to eat and digest food...
- Pediatric Imaging Original Research MRI and Biologic Behavior of Desmoid Tumors in Children
McCarville et al. - The outcome of desmoid tumor in children cannot be reliably predicted on the basis of histologic findings. We sought to determine whether the postoperative presence of residual or recurrent tumor can be predicted on the basis of demographic variables and baseline MRI features of the tumor. We also aimed to determine how imaging features change during adjuvant treatment and how the imaging features relate to the histologic features.
- "The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients." A study of the Rare Cancer Network.
Brigitta G Baumert, et al. - Conclusions: Postoperative radiotherapy significantly improved the PFS compared to surgery alone. Therefore it should always be considered after a non-radical tumour resection and should be given preferably in an adjuvant setting. It is effective in limb preservation and for preserving the function of joints in situations where surgery alone would result in deficits, which is especially important in young patients...
- Illinois boy's rare and aggressive tumor challenges specialists at Children's Hospital of Iowa
- Gardner's syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapy
- CT scanning gives the best information on tumour anatomy whilst T2-weighted MRI indicates likely behaviour. So, the choice of scan type would seem to depend on what info your doctor is looking for.
- Report on the cardiac issues with Gleevec
- Radiation Therapy for Aggressive Fibromatosis
- Study: Cancer Drug May Pose Heart Danger
- Gleevec's long term effects on bone and mineral metabolism
- HIFU ( high intensity focused ultrasound) for soft tissue tumors
|
|
|
